Status:
COMPLETED
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Non-squamous, Non-Small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Brief Summary
The primary objective is to confirm Time on Treatment (TOT) related to afatinib treatment as first-line therapy in patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cel...
Eligibility Criteria
Inclusion
- Patients with Epidermal Growth Factor Receptor (EGFR) mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC)
- Patients who were/are treated with afatinib in the first-line setting at least 20 months\* prior to data entry
- Patients 20 years of age or older at the time of consent
- Patients who provided consent to participate in this study (for cases of death or lost to follow-up, instructions from the Ethic Committee (EC)/Institutional Review Board (IRB) at each site should be followed) \* Inclusion will be restricted to patients with treatment initiation with afatinib at least 20 months prior to enrolment to avoid early censoring.
Exclusion
- Any contraindication to afatinib as specified in the label of Giotrif®
- Patients treated with afatinib within an interventional trial
- Patients with active brain metastases at start of afatinib treatment\* \* Patients with non-active brain metastases (asymptomatic state) are eligible.
Key Trial Info
Start Date :
August 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 16 2023
Estimated Enrollment :
805 Patients enrolled
Trial Details
Trial ID
NCT04795245
Start Date
August 26 2021
End Date
October 16 2023
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, Japan, 141-6017